Prelude Capital Management LLC, a prominent investment management firm, recently acquired a new stake in Sarepta Therapeutics, Inc. during the first quarter of this year. The company disclosed this information in its most recent 13F filing with the Securities & Exchange Commission. Prelude Capital Management acquired 3,501 shares of Sarepta Therapeutics, valued at approximately $483,000.
Sarepta Therapeutics (NASDAQ:SRPT) released its quarterly earnings data on August 2nd, providing insight into its financial performance. Despite expectations of negative earnings per share for the quarter, the biotechnology company reported ($0.27) per share – an impressive beat compared to the consensus estimate of ($1.89). This positive outcome exceeded market expectations and further strengthened investor confidence in Sarepta Therapeutics.
Furthermore, Sarepta Therapeutics demonstrated encouraging growth in terms of its revenue for the quarter. The firm generated $261.20 million in revenue during this period – surpassing analysts’ projections of $255.99 million and indicating an 11.9% increase from the previous year’s results.
Although Sarepta Therapeutics has experienced losses in past years and still possesses a negative net margin of 90.46% and return on equity of 91.22%, these latest earnings results offer signs of potential improvement for the company’s financial health.
Equities research analysts have been closely monitoring Sarepta Therapeutics’ performance and have offered various perspectives on its stock value. Barclays recently raised their target price on shares of Sarepta Therapeutics from $170.00 to $193.00 in their research note dated June 23rd. On the other hand, Evercore ISI lowered their price objective for Sarepta Therapeutics from $173.00 to $151.00 based on market analysis conducted on May 30th.
Bank of America holds a more optimistic view and has increased their price objective from $176.00 to $186.00. Similarly, JPMorgan Chase & Co. maintained a positive outlook but reduced their price objective from $217.00 to $213.00 following comprehensive research conducted on June 23rd.
In a research note published on August 17th, StockNews.com initiated coverage on Sarepta Therapeutics and marked the stock as “hold.” Currently, the average rating for the company is deemed as “Moderate Buy,” according to Bloomberg.com. With a consensus target price of $173.70, Sarepta Therapeutics has captured the attention of both seasoned investors and industry experts.
As September 17, 2023 approaches, investors remain keenly interested in monitoring the performance of Sarepta Therapeutics and how it will navigate the challenges and opportunities that lie ahead. With its latest quarterly earnings exceeding expectations and receiving positive ratings from analysts, Sarepta Therapeutics has solidified itself as a biotechnology company with potential for growth in the coming years.
Delta Air Lines, Inc.
DAL
Strong Buy
Updated on: 04/12/2023
Very Healthy 
Investment Patterns and Insider Transactions Highlighting Interest in Sarepta Therapeutics’ Stock
Sarepta Therapeutics, a leading biotechnology company, has seen recent changes in its stock holdings as several hedge funds and institutional investors have modified their positions. Macquarie Group Ltd., for instance, increased its stake in Sarepta Therapeutics by 2.0% during the first quarter of this year. The group now owns 26,124 shares of the company’s stock, valued at $3,601,000. Similarly, Rockefeller Capital Management L.P. raised its stake by 38.1% during the same period and now owns 4,142 shares worth $570,000.
Interestingly, KB Financial Partners LLC also made a significant move by acquiring a new stake in Sarepta Therapeutics valued at approximately $36,000 during the first quarter. Mercer Global Advisors Inc. ADV also joined in with a new stake worth around $300,000 in the same period. Finally, Sphera Funds Management LTD. acquired a considerable stake in Sarepta Therapeutics worth approximately $6,065,000.
These moves highlight the level of interest among hedge funds and institutional investors towards Sarepta Therapeutics’ stock. In fact, such financial entities currently own an impressive 91.82% of the company’s stock.
In other news concerning Sarepta Therapeutics’ leadership team and insiders within the organization, Director Michael Andrew Chambers made a significant acquisition of the firm’s stock on August 10th. Chambers purchased 34,867 shares at an average cost of $106.15 per share—an investment totaling $3,701,132.05. Following this acquisition, Chambers now holds a direct ownership position of 213,331 shares with an estimated value of $22,645,085.65.
Similarly noteworthy is Director Hans Lennart Rudolf Wigzell’s recent sale of 15,000 shares on August 4th at an average price of $106.72 per share. This transaction resulted in a total sale value of $1,600,800.00. Following the sale, Wigzell currently holds 20,994 shares with an approximate value of $2,240,479.68.
Sarepta Therapeutics’ stock opened at $118.40 on September 17th. The company’s financials demonstrate a quick ratio of 4.50 and a current ratio of 4.96, signifying its ability to meet short-term obligations efficiently. Additionally, Sarepta Therapeutics has a debt-to-equity ratio of 1.67.
Over the past 50 days, the stock has shown a moving average price of $112.04, whereas over the past 200 days, it has demonstrated a moving average price of $124.39—a noteworthy difference between short-term and long-term trends in market prices for Sarepta Therapeutics’ shares.
It is important to note that Sarepta Therapeutics’ stock performance over the past twelve months indicates that its lowest point was $100.15, while its highest reached $159.89—an appreciable fluctuation in market valuation within this timeframe.
Currently boasting a market capitalization of approximately $10.42 billion, Sarepta Therapeutics maintains a negative price-to-earnings ratio of -11.48 and beta coefficient of 0.94—a measure indicating its sensitivity to market volatility as compared to broader market indices.
These recent developments in both investment patterns from hedge funds and institutional investors and insider transactions by directors serve as notable indicators for investors interested in assessing the prospects and opportunities associated with investing in Sarepta Therapeutics’ stock.
Discussion about this post